Navigation Links
Highest Genomic Replikin Counts Found in Antibiotic-Resistant Bacteria
Date:3/14/2013

OTTAWA, Ontario, March 14, 2013 /PRNewswire/ -- A group of lethal bacteria are of increasing concern worldwide because they are becoming resistant to many or all of the antibiotics previously effective against them (1). Bioradar UK Ltd. announced today in Ottawa, Canada that it has discovered that the concentration of genomic Replikins is markedly increased in antibiotic-resistant bacteria. This finding is permitting a new approach to the problem of antibiotic resistance.

(Photo: http://photos.prnewswire.com/prnh/20130314/PH76883 )

The specific change in the Replikins genomic structure of the Replikins provides a novel target: proprietary Replikins Synthetic Vaccines like those found effective against H5N1 influenza in poultry and lethal Taura Syndrome virus in shrimp, have been formulated, and which are now available for testing against lethal antibiotic-resistant Gonococcus, Tuberculosis, Staphylococcus, Streptococcus, Klebsiella KPC, and Cl. Difficile.

For example, in Replikin Analysis of antibiotic-sensitive-Gonococcus, in all 5,110 genomic sequences on Pubmed, the percent of the gonococcus population with Replikin®Counts above 4.0 is only 3%; but in antibiotic-resistant-Gonococcus, the percent in the gonococcus genome with Replikin®Counts greater than 4.0 increased to 95% in tetracycline-resistant Gonococcus (Figure).  

In Cl. Difficile, in sequences from 86,581 specimens, the percent of Replikin®Counts greater than 4.0 was found to increase from approximately 30% in the year 2000 to 45.6% in 2007 and has remained at that level to 2012. Similar data were obtained in Staphylococcus, with 86% above a Count of 4.0 in 2006, and in Streptococcus, with 65% above a Count of 4.0 in 2009 (2).

When an association of genomic Replikins was first observed in Tuberculosis (3), there was no reason to assume that this was a general genomic structural property of resistance in bacteria. However upon Replikins Analyses of 123,704 genomic sequences from several pathogenic bacteria published in Pubmed, the unexpected discovery was made that when bacterial resistance develops, for example in all six of the above named bacteria of concern, there is a marked increase in the genomic Replikin®Counts (number of genomic Replikins per 100 amino acids) (p<0.001). Replikin®Counts of 0.1 to 4.0 were found in antibiotic-sensitive bacteria; antibiotic-resistant bacteria isolates had Replikin®Counts greater than 4.0, which ranged from 4.1 to 50. Thus as the resistance to antibiotics of that bacterial population increased, the percent of Replikin®Counts in that bacterial population increased.

As new Replikins are added to or disappear from the genome during bacterial evolution, certain individual Replikins remain conserved for decades, making long-acting vaccines possible (3,4). This shared genomic structural property shared by different antibiotic-resistant bacterial strains presents a new platform in bacterial genomic structure for specific early diagnosis, vaccines, and therapies. Effective Replikins vaccines have been synthesized more cheaply than the cost of biological vaccines (10 cents vs 11 dollars), and in 7 days rather than 8 months, and by solid phase synthesis in virtually unlimited amounts, rather than only approximately 1.25 billion doses in 8 months as in the 2009 H1N1 pandemic; lacking the potential for side effects due to biological contaminants, and shipped freeze-dried without refrigeration.

Another consequence of this finding in the genomes of infectious diseases is the ability for the first time to predict outbreaks in advance, providing time to respond well in advance of the outbreak.  Before this work on bacteria, earlier studies by our companies on viruses, including influenza, found that when the virus genomes contained increasing concentrations of Replikins, outbreaks of these specific viruses, and the geographic sites of these outbreaks, were predicted one to two years in advance of the outbreak. Twelve out of twelve such correct predictions, based on Replikin®Counts alone, have been made and most published in prospective trials in the past 9 years, including Replikins' 2008 prediction of the coming 2009 H1N1 influenza pandemic (3,4).

Retrospectively, the prediction by Replikin®Counts of outbreaks also was found in all influenza pandemics and major outbreaks in the past century (3,4). The companies' resulting H5N1 vaccine (ReplikinsSyntheticTrans-FluTMVaccine), has been successful in poultry in blocking virus entry, replication and excretion, and Replikins Taura Syndrome Virus Vaccine has protected 91% of shrimp against this fatal virus. Both vaccines were produced in 7 days and shipped freeze-dried (3,4).

For licenses to test, distribute and market these new Replikins diagnostics, vaccines and therapies against antibiotic-resistant bacteria, please email Samuel Bogoch or call 646-320-5910.

References

  1. Cressey, Daniel..Nature News Blog, 11 Mar 2013
  2. Bogoch,S. and Bogoch ES. Killer Replikins, in the Genomes of Lethal Viruses, Antibiotic-Resistant Bacteria, Malaria and Cancer. In press 2013.
  3. Bogoch S. and Bogoch ES. Nature Precedings. Eight publications, 2011-2012.
  4. Website <Replikins>

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
2. New Torrent Suite Software Provides Highest Accuracy and 400 Base Pair Kits Deliver Broader Applications for Ion Semiconductor Sequencing
3. DuPont Congratulates David Hula for Highest Overall Yield with Pioneer® hybrid – P2088YHR in 2012 NCGA Corn Yield Contest
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
6. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
7. Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
8. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
9. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
10. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
11. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... 2016   Merck , a leading science and ... a set of agreements with Evotec AG, whereby Evotec ... genetic reagents such as CRISPR and shRNA libraries. Combining ... an accelerated pathway to explore and identify new drug ... of new targets, a process that can be time- ...
(Date:11/30/2016)... ... 2016 , ... On 28 November 2016, the International Union of Pure and ... moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, 117, and ... the discoverers have been approved by the IUPAC Bureau. The IUPAC Council will be ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
Breaking Biology News(10 mins):